Therapeutic Effect of Oral Bisphosphonates on Choroidal Neovascularization in the Human Eye
Open Access
- 25 July 2010
- journal article
- research article
- Published by Hindawi Limited in Journal of Ophthalmology
- Vol. 2010, 1-7
- https://doi.org/10.1155/2010/206837
Abstract
Purpose. Choroidal neovascularization (CNV) is often associated with age-related macular degeneration (AMD) and pathological myopia (PM). Bisphosphonates, the drug of choice to treat osteoporosis, have been recently reported to have anti-angiogenic effects. The purpose of this study is to investigate the therapeutic effects of oral bisphosphonates for CNV in humans.Methods. Thirty-six consecutive cases with CNV due to AMD or PM who declined anti-VEGF therapy were recruited. The patients were prescribed 5 mg of oral alendronates daily for 6 months. The best-corrected visual-acuity (BCVA), the lesion size in fundus photographs and fluorescein angiography, foveal thickness and total macular volume in optical coherence tomography were compared between pre- and post-treatment.Results. The mean BCVA of the patients was significantly improved after a months with the treatment in the AMD group. In the PM group, the mean BCVA was maintained up to 6 months with the treatment. The mean lesion size was significantly decreased by 3 months in both groups. The averages of foveal thickness and total macular volume were significantly reduced after 1 month of treatment in the AMD group.Conclusions. Oral bisphosphonate should be further investigated as a possible therapeutic and preventive drug for CNV due to AMD and PM.This publication has 33 references indexed in Scilit:
- Forecasting Age-Related Macular Degeneration Through the Year 2050JAMA Ophthalmology, 2009
- INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMABRetina, 2008
- Clinicopathologic Findings in Polypoidal Choroidal VasculopathyInvestigative Ophthalmology & Visual Science, 2008
- Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Injections in An Office SettingAmerican Journal of Ophthalmology, 2008
- Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer PatientsClinical Cancer Research, 2007
- Age-related macular degeneration and recent developments: new hope for old eyes?Published by Oxford University Press (OUP) ,2007
- Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cellsBiochemical and Biophysical Research Communications, 2007
- Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?Recent Patents on Anti-Cancer Drug Discovery, 2006
- Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side EffectsOphthalmology, 2004
- Macrophage Depletion Inhibits Experimental Choroidal NeovascularizationInvestigative Ophthalmology & Visual Science, 2003